Skip to main content
Top
Published in: Infection 1/2020

01-02-2020 | Heart Surgery | Original Paper

Virulence of beta-hemolytic streptococci in infective endocarditis

Authors: Yvon Ruch, Yves Hansmann, Philippe Riegel, Nicolas Lefebvre, Jean-Philippe Mazzucotelli, Nawal Douiri, Aurélie Martin, Xavier Argemi

Published in: Infection | Issue 1/2020

Login to get access

Abstract

Background

Streptococci involved in infective endocarditis (IE) primarily comprise alpha- or non-hemolytic streptococci (ANHS). Moreover, beta-hemolytic streptococci (BHS) can be involved, and guidelines recommend the addition of gentamicin for the first 2 weeks of treatment and the consideration of early surgery in such cases. This study compared the morbidity and mortality associated with IE depending on the microorganisms involved (BHS, ANHS, staphylococci, and enterococci).

Methods

We conducted a retrospective observational study between 2012 and 2017 in a single hospital in France. The endpoints were overall in-hospital mortality, 1-year mortality and the occurrence of complications.

Results

We analyzed 316 episodes of definite IE including 150 (38%), 96 (25%), 46 (12%), and 24 cases (6%) of staphylococcal, ANHS, enterococcal, and BHS IE, respectively. In-hospital mortality was significantly higher in the staphylococcal (n = 40; 26.7%) and BHS groups (n = 6; 25.0%) than in the ANHS (n = 9; 9.4%) and enterococcal groups (n = 5; 10.9%) (all p < 0.01). The rates of septic shock and cerebral emboli were also higher in the BHS group than in the ANHS group [n = 7 (29.2%) vs. n = 3 (3.1%), p < 0.001; n = 7 (29.2%) vs. n = 12 (12.5%); p = 0.05, respectively].

Conclusion

This study confirmed that BHS IE has a more severe prognosis than ANHS IE. The virulence of BHS may be similar to that of staphylococci, justifying increased monitoring of these patients and more ‘aggressive’ treatments such as early surgery.
Appendix
Available only for authorised users
Literature
1.
go back to reference Slipczuk L, Codolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS, et al. Infective endocarditis epidemiology over five decades: a systematic review. PLoS One. 2013;8:e82665.CrossRef Slipczuk L, Codolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS, et al. Infective endocarditis epidemiology over five decades: a systematic review. PLoS One. 2013;8:e82665.CrossRef
2.
go back to reference Duval X, Delahaye F, Alla F, Tattevin P, Obadia J-F, Le Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012;59:1968–76.CrossRef Duval X, Delahaye F, Alla F, Tattevin P, Obadia J-F, Le Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012;59:1968–76.CrossRef
3.
go back to reference Sy RW, Kritharides L. Health care exposure and age in infective endocarditis: results of a contemporary population-based profile of 1536 patients in Australia. Eur Heart J. 2010;31:1890–7.CrossRef Sy RW, Kritharides L. Health care exposure and age in infective endocarditis: results of a contemporary population-based profile of 1536 patients in Australia. Eur Heart J. 2010;31:1890–7.CrossRef
4.
go back to reference Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, et al. Clinical presentation, etiology and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. Arch Intern Med. 2009;169:463–73.CrossRef Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, et al. Clinical presentation, etiology and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. Arch Intern Med. 2009;169:463–73.CrossRef
5.
go back to reference Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075–128.CrossRef Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075–128.CrossRef
6.
go back to reference Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the american heart association. Circulation. 2015;132:1435–86.CrossRef Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the american heart association. Circulation. 2015;132:1435–86.CrossRef
7.
go back to reference Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801–10.CrossRef Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801–10.CrossRef
8.
go back to reference Baddour LM. Infective endocarditis caused by beta-hemolytic streptococci. The infectious diseases society of America’s emerging infections network. Clin Infect Dis. 1998;26:66–71.CrossRef Baddour LM. Infective endocarditis caused by beta-hemolytic streptococci. The infectious diseases society of America’s emerging infections network. Clin Infect Dis. 1998;26:66–71.CrossRef
9.
go back to reference Lefort A, Lortholary O, Casassus P, Selton-Suty C, Guillevin L, Mainardi J-L, et al. Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. Arch Intern Med. 2002;162:2450–6.CrossRef Lefort A, Lortholary O, Casassus P, Selton-Suty C, Guillevin L, Mainardi J-L, et al. Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. Arch Intern Med. 2002;162:2450–6.CrossRef
10.
go back to reference Ekelund K, Skinhøj P, Madsen J, Konradsen HB. Invasive group A, B, C and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects. Clin Microbiol Infect. 2005;11:569–76.CrossRef Ekelund K, Skinhøj P, Madsen J, Konradsen HB. Invasive group A, B, C and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects. Clin Microbiol Infect. 2005;11:569–76.CrossRef
11.
go back to reference Rantala S, Vuopio-Varkila J, Vuento R, Huhtala H, Syrjänen J. Clinical presentations and epidemiology of beta-haemolytic streptococcal bacteraemia: a population-based study. Clin Microbiol Infect. 2009;15:286–8.CrossRef Rantala S, Vuopio-Varkila J, Vuento R, Huhtala H, Syrjänen J. Clinical presentations and epidemiology of beta-haemolytic streptococcal bacteraemia: a population-based study. Clin Microbiol Infect. 2009;15:286–8.CrossRef
12.
go back to reference Oppegaard O, Mylvaganam H, Kittang BR. Beta-haemolytic group A, C and G streptococcal infections in Western Norway: a 15-year retrospective survey. Clin Microbiol Infect. 2015;21:171–8.CrossRef Oppegaard O, Mylvaganam H, Kittang BR. Beta-haemolytic group A, C and G streptococcal infections in Western Norway: a 15-year retrospective survey. Clin Microbiol Infect. 2015;21:171–8.CrossRef
13.
go back to reference El Rafei A, DeSimone DC, DeSimone CV, Lahr BD, Steckelberg JM, Sohail MR, et al. Beta-haemolytic streptococcal endocarditis: clinical presentation, management and outcomes. Infect Dis. 2016;48:373–8.CrossRef El Rafei A, DeSimone DC, DeSimone CV, Lahr BD, Steckelberg JM, Sohail MR, et al. Beta-haemolytic streptococcal endocarditis: clinical presentation, management and outcomes. Infect Dis. 2016;48:373–8.CrossRef
14.
go back to reference Sambola A, Miro JM, Tornos MP, Almirante B, Moreno-Torrico A, Gurgui M, et al. Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962–1998. Clin Infect Dis. 2002;34:1576–84.CrossRef Sambola A, Miro JM, Tornos MP, Almirante B, Moreno-Torrico A, Gurgui M, et al. Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962–1998. Clin Infect Dis. 2002;34:1576–84.CrossRef
15.
go back to reference Rollán MJ, San Román JA, Vilacosta I, Sarriá C, López J, Acuña M, et al. Clinical profile of Streptococcus agalactiae native valve endocarditis. Am Heart J. 2003;146:1095–8.CrossRef Rollán MJ, San Román JA, Vilacosta I, Sarriá C, López J, Acuña M, et al. Clinical profile of Streptococcus agalactiae native valve endocarditis. Am Heart J. 2003;146:1095–8.CrossRef
16.
go back to reference Ivanova-Georgieva R, Ruiz-Morales J, García-Cabrera E, García-López MV, Gálvez-Acebal J, Plata-Ciezar A, et al. Left-sided infective endocarditis caused by Streptococcus agalactiae: rare and serious. Eur J Clin Microbiol Infect Dis. 2019;38:265–75.CrossRef Ivanova-Georgieva R, Ruiz-Morales J, García-Cabrera E, García-López MV, Gálvez-Acebal J, Plata-Ciezar A, et al. Left-sided infective endocarditis caused by Streptococcus agalactiae: rare and serious. Eur J Clin Microbiol Infect Dis. 2019;38:265–75.CrossRef
17.
go back to reference Olmos C, Vilacosta I, Sarriá C, López J, Ferrera C, Sáez C, et al. Streptococcus bovis endocarditis: update from a multicenter registry. Am Heart J. 2016;171:7–13.CrossRef Olmos C, Vilacosta I, Sarriá C, López J, Ferrera C, Sáez C, et al. Streptococcus bovis endocarditis: update from a multicenter registry. Am Heart J. 2016;171:7–13.CrossRef
18.
go back to reference Bläckberg A, Nilson B, Özenci V, Olaison L, Rasmussen M. Infective endocarditis due to Streptococcus dysgalactiae: clinical presentation and microbiological features. Eur J Clin Microbiol Infect Dis. 2018;37:2261–72.CrossRef Bläckberg A, Nilson B, Özenci V, Olaison L, Rasmussen M. Infective endocarditis due to Streptococcus dysgalactiae: clinical presentation and microbiological features. Eur J Clin Microbiol Infect Dis. 2018;37:2261–72.CrossRef
19.
go back to reference Wang A, Athan E, Pappas PA, Fowler VG, Olaison L, Paré C, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA. 2007;297:1354–61.CrossRef Wang A, Athan E, Pappas PA, Fowler VG, Olaison L, Paré C, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA. 2007;297:1354–61.CrossRef
20.
go back to reference Mahesh B, Angelini G, Caputo M, Jin XY, Bryan A. Prosthetic valve endocarditis. Ann Thorac Surg. 2005;80:1151–8.CrossRef Mahesh B, Angelini G, Caputo M, Jin XY, Bryan A. Prosthetic valve endocarditis. Ann Thorac Surg. 2005;80:1151–8.CrossRef
21.
go back to reference Sendi P. Infective endocarditis caused by Streptococcus agalactiae: time for beta-hemolytic streptococci to follow treatment recommendations for S. aureus? Eur J Clin Microbiol Infect Dis. 2019;38:419–22.CrossRef Sendi P. Infective endocarditis caused by Streptococcus agalactiae: time for beta-hemolytic streptococci to follow treatment recommendations for S. aureus? Eur J Clin Microbiol Infect Dis. 2019;38:419–22.CrossRef
22.
go back to reference Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. 2012;54:1230–9.CrossRef Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. 2012;54:1230–9.CrossRef
23.
go back to reference Day MD, Gauvreau K, Shulman S, Newburger JW. Characteristics of children hospitalized with infective endocarditis. Circulation. 2009;119:865–70.CrossRef Day MD, Gauvreau K, Shulman S, Newburger JW. Characteristics of children hospitalized with infective endocarditis. Circulation. 2009;119:865–70.CrossRef
24.
go back to reference Weidman DR, Al-Hashami H, Morris SK. Two cases and a review of Streptococcus pyogenes endocarditis in children. BMC Pediatr. 2014;14:227.CrossRef Weidman DR, Al-Hashami H, Morris SK. Two cases and a review of Streptococcus pyogenes endocarditis in children. BMC Pediatr. 2014;14:227.CrossRef
25.
go back to reference Chu VH, Park LP, Athan E, Delahaye F, Freiberger T, Lamas C, et al. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis. Circulation. 2015;131:131–40.CrossRef Chu VH, Park LP, Athan E, Delahaye F, Freiberger T, Lamas C, et al. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis. Circulation. 2015;131:131–40.CrossRef
Metadata
Title
Virulence of beta-hemolytic streptococci in infective endocarditis
Authors
Yvon Ruch
Yves Hansmann
Philippe Riegel
Nicolas Lefebvre
Jean-Philippe Mazzucotelli
Nawal Douiri
Aurélie Martin
Xavier Argemi
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 1/2020
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-019-01358-7

Other articles of this Issue 1/2020

Infection 1/2020 Go to the issue

Images in Infection

Severe malaria

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.